Praveen Ratanasrimetha Vikas D Reddy Jaya Kala Amanda Tchakarov William F Glass Pavlos Msaouel Jamie S Lin
10.3389/fimmu.2022.898811
Front Immunol
2022 Jul 28;13:898811.
case report immune checkpoint inhibitor (ici) immune related adverse events (iraes) membranous nephropathy (mn) proteinuria renal cell carcinoma (rcc) rituximab
CC BY
https://pubmed.ncbi.nlm.nih.gov/35967405/
Carcinoma, Renal Cell / diagnosis Carcinoma, Renal Cell / drug therapy Glomerulonephritis, Membranous / chemically induced Glomerulonephritis, Membranous / diagnosis Glomerulonephritis, Membranous / drug therapy
Carcinoma, Renal Cell / diagnosis Carcinoma, Renal Cell / drug therapy Glomerulonephritis, Membranous / chemically induced Glomerulonephritis, Membranous / diagnosis Glomerulonephritis, Membranous / drug therapy Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Humans Immune Checkpoint Inhibitors / adverse effects Male Middle Aged Receptors, Phospholipase A2 Immune Checkpoint Inhibitors Receptors, Phospholipase A2 Clear-cell metastatic renal cell carcinoma
PMC9366044
35967405
Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma
2022